Join Growin Stock Community!

Bioventus inc.BVS.US Overview

US StockHealthcare
(No presentation for BVS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BVS AI Insights

BVS Overall Performance

BVS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BVS Recent Performance

-2.88%

Bioventus inc.

0.05%

Avg of Sector

-0.31%

S&P500

BVS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BVS Key Information

BVS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BVS Profile

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Price of BVS

BVS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BVS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.12
PE Ratio (TTM)
54.88
Forward PE
9.22
PS Ratio (TTM)
1.04
PB Ratio
3.55
Price-to-FCF
10.68
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.76%
Net Margin
1.39%
Revenue Growth (YoY)
1.58%
Profit Growth (YoY)
2.73%
3-Year Revenue Growth
2.52%
3-Year Profit Growth
3.69%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.12
PE Ratio (TTM)
54.88
Forward PE
9.22
PS Ratio (TTM)
1.04
PB Ratio
3.55
Price-to-FCF
10.68
Gross Margin
67.76%
Net Margin
1.39%
Revenue Growth (YoY)
1.58%
Profit Growth (YoY)
2.73%
3-Year Revenue Growth
2.52%
3-Year Profit Growth
3.69%
  • When is BVS's latest earnings report released?

    The most recent financial report for Bioventus inc. (BVS) covers the period of 2025Q3 and was published on 2025/09/27. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BVS's short-term business performance and financial health. For the latest updates on BVS's earnings releases, visit this page regularly.

  • What is the operating profit of BVS?

    According to the latest financial report, Bioventus inc. (BVS) reported an Operating Profit of 4.67M with an Operating Margin of 3.37% this period, representing a growth of 207.36% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BVS's revenue growth?

    In the latest financial report, Bioventus inc. (BVS) announced revenue of 138.65M, with a Year-Over-Year growth rate of -0.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BVS have?

    As of the end of the reporting period, Bioventus inc. (BVS) had total debt of 322.58M, with a debt ratio of 0.46. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BVS have?

    At the end of the period, Bioventus inc. (BVS) held Total Cash and Cash Equivalents of 42.16M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BVS go with three margins increasing?

    In the latest report, Bioventus inc. (BVS) achieved the “three margins increasing” benchmark, with a gross margin of 68%%, operating margin of 3.37%%, and net margin of 2.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BVS's profit trajectory and future growth potential.

  • Is BVS's EPS continuing to grow?

    According to the past four quarterly reports, Bioventus inc. (BVS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BVS?

    Bioventus inc. (BVS)'s Free Cash Flow (FCF) for the period is 29.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 188.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BVS?

    The latest valuation data shows Bioventus inc. (BVS) has a Price-To-Earnings (PE) ratio of 79.9 and a Price/Earnings-To-Growth (PEG) ratio of -0.65. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.